Now it’s time to focus on investments.
Marin Katusa’s focus is on identifying the next buyout targets, companies trading at a fraction of their true value.
As big names like Barrick and Newmont look to scoop up smaller producers, the window of opportunity to buy these hidden gems is shrinking.
This is where you want your money before the buyout headlines hit.
Mining’s Biotech Moment: The ‘Phase 3’ Strategy
In his recent interview with Porter Stansberry, Marin Katusa draws a brilliant comparison: gold investing today is like biotech investing.
In biotech, the early-stage plays are a gamble, but when a drug passes Phase 3 trials, the upside is almost guaranteed.
The same applies to mining—don’t bet on speculative explorers. Focus on assets that have proven their value.
Marin’s strategy is to invest in companies with proven reserves and completed studies, the equivalent of Phase 3 drugs in the mining world.
This is where the majors step in, offering massive premiums to snap up these de-risked assets.
Forget chasing long-shot “ten-baggers”
Marin’s focus is on real, attainable profits.
He’s targeting stocks that can realistically triple in value—without the wild risk that comes from investing in juniors or speculative plays.
Warning: You still have to have a HIGH RISK tolerance, no doubt.
These aren’t lottery tickets…
Marin’s making smart, calculated investments in companies with proven assets, strong management teams, and favorable market conditions.
And laser-focused on identifying the few opportunities that can deliver consistently.
Discover the next BUYOUT targets now.
Regards,
Anthony Ford
Publisher, Katusa Research |
|
